Intuitive Surgical Sales Rise 22% To $3.05 Billion, But $450 Million Settlement Cuts Reported Profit
Adjusted earnings reached $3.00 a share, while standard-accounting net income fell to $1.49 a share after the antitrust settlement charge.
Intuitive Surgical, the maker of da Vinci surgical robots, reported third-quarter revenue of $3.05 billion, up 22% from $2.51 billion a year earlier, in an 8-K filed Tuesday. A $450 million pre-tax charge to settle an antitrust class action pushed standard-accounting net income down to $523 million, or $1.49 a share, from $704 million, or $1.95.
Sales up, reported profit down
The company said the revenue gain came from higher procedure volume, more operating lease revenue and a bigger installed base. Instruments and accessories revenue rose 18% to $1.80 billion from $1.52 billion. Systems revenue was $769 million, versus $590 million a year earlier.
The settlement charge, booked in selling, general and administrative expenses, cost $347 million after tax, or $0.99 per diluted share. Standard-accounting operating income fell to $593 million from $760 million.
On the company's adjusted measure, net income rose to $1.05 billion, or $3.00 a share, from $867 million, or $2.40. Adjusted operating income was $1.27 billion, versus $976 million. Both the reported and adjusted figures include a $22 million after-tax benefit, or $0.06 a share, from refunds of tariffs paid in earlier periods under the International Emergency Economic Powers Act.
Procedures, placements and cash
Worldwide procedures grew about 15%. Da Vinci procedures rose about 14% and Ion, the company's lung-focused system, about 31%.
The company placed 546 da Vinci systems, 315 of them da Vinci 5, versus 427 and 240 a year earlier. The da Vinci installed base reached 12,094 at September 30, up 12% from 10,763.
Intuitive bought back 7.8 million shares for $2.94 billion. It ended the quarter with $6.80 billion in cash and investments, down $1.83 billion during the quarter, which it attributed mainly to buybacks and spending on property, plant and equipment, partly offset by operating cash flow.
CEO Dave Rosa said customers used the systems for "over 10,000 procedures per day" on average during the period.
Outlook and the settlement's next steps
For 2026 the company expects da Vinci procedure growth of about 14% to 15%, closer to the midpoint. It guides to an adjusted gross margin of 68.7% to 69.3%, a range that includes a 0.9% of revenue tariff impact, and adjusted operating expense growth of 11% to 13%.
That margin range assumes current tariffs stay in place through year-end. The company warned that additional tariffs could have a material effect.
The settlement, reached in October after a mediation, includes mutually agreed injunctive relief and no admission of liability. It still needs preliminary and final court approval, and class members may object.
The company's call to discuss the quarter was set for 1:30 p.m. PDT on Tuesday.
Sources
- 8-K Filing — INTUITIVE SURGICAL INC (ISRG) — SEC EDGAR
- Exhibit q326ex-991earningsrelease.htm — INTUITIVE SURGICAL INC 8-K exhibit — SEC EDGAR
- Why ISRG Is Lowering Instrument Costs Despite Strong Profitability — Yahoo Finance
- ISRG Ahead of Q3 Earnings: Can Procedure Growth Sustain Momentum? — Yahoo Finance